Intranasal inoculation with an adenovirus vaccine encoding ten repeats of Aβ3-10 reduces AD-like pathology and cognitive impairment in Tg-APPswe/PSEN1dE9 mice

Journal of Neuroimmunology

Volumn 249, Issue 1-2, 2012, Pages 16-26

  Li, Yu ^a   Ma, Ying ^a   Zong, Li Xia ^a   Xing, Xiao Na ^a   Guo, Rong ^b   Jiang, Tong Zi ^a   Sha, Sha ^a   Liu, Li ^a   Cao, Yun Peng ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Shenyang Red Cross Hospital   (China)

Author keywords

Adenovirus vaccine; Alzheimer's disease; Amyloid beta; Astrocytes; Immunotherapy

Indexed keywords

ADENOVIRUS VECTOR; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[3-10]; GLYCOPROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; ASTROCYTOSIS; BRAIN HEMORRHAGE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMORAL IMMUNITY; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TH2 CELL;

ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; COGNITION DISORDERS; CPG ISLANDS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC VECTORS; IMMUNOHISTOCHEMISTRY; MALE; MAZE LEARNING; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS;

EID: 84863430558     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.04.014     Document Type: Article

References (57)

1. Abbas A.K., Murphy K.M., Sher A. Functional diversity of helper T lymphocytes. Nature 1996, 383:787-793.
2. Afzali B., Lombardi G., Lechler R.I., Lord G.M. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin. Exp. Immunol. 2007, 148:32-46.
3. Allaman I., Gavillet M., Bélanger M., Laroche T., Viertl D., Lashuel H.A., Magistretti P.J. Amyloid-beta aggregates cause alterations of astrocytic metabolic phenotype: impact on neuronal viability. J. Neurosci. 2010, 30:3326-3338.
4. Bacskai B.J., Kajdasz S.T., McLellan M.E., Games D., Seubert P., Schenk D., Hyman B.T. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J. Neurosci. 2002, 22:7873-7878.
5. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 2000, 6:916-919.
6. Bard F., Barbour R., Cannon C., Carretto R., Fox M., Games D., Guido T., Hoenow K., Hu K., Johnson-Wood K., Khan K., Kholodenko D., Lee C., Lee M., Motter R., Nguyen M., Reed A., Schenk D., Tang P., Vasquez N., Seubert P., Yednock T. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2023-2028.
7. Berzofsky J.A., Ahlers J.D., Belyakov I.M. Strategies for designing and optimizing new generation vaccines. Nat. Rev. Immunol. 2001, 1:209-219.
8. Chauhan N.B., Siegel G.J. Efficacy of anti-Abeta antibody isotypes used for intracerebroventricular immunization in TgCRND8. Neurosci. Lett. 2005, 375:143-147.
9. Cribbs D.H., Ghochikyan A., Vasilevko V., Tran M., Petrushina I., Sadzikava N., Babikyan D., Kesslak P., Kieber-Emmons T., Cotman C.W., Agadjanyan M.G. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int. Immunol. 2003, 15:505-514.
10. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:8850-8855.
11. DeMattos R.B., Bales K.R., Cummins D.J., Paul S.M., Holtzman D.M. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002, 295:2264-2267.
12. Ferrer I., Boada Rovira M., Sánchez Guerra M.L., Rey M.J., Costa-Jussá F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 2004, 14:11-20.
13. Frenkel D., Kariv N., Solomon B. Generation of auto-antibodies towards Alzheimer's disease vaccination. Vaccine 2001, 19:2615-2619.
14. Funato H., Yoshimura M., Yamazaki T., Saido T.C., Ito Y., Yokofujita J., Okeda R., Ihara Y. Astrocytes containing amyloid betaprotein (Abeta)-positive granules are associated with Abeta40-positive diffuse plaques in the aged human brain. Am. J. Pathol. 1998, 152:983-992.
15. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., Eisner L., Kirby L., Rovira M.B., Forette F., Orgogozo J.M., AN1792(QS-21)-201 Study Team Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562.
16. Halonen M., Lohman I.C., Stern D.A., Spangenberg A., Anderson D., Mobley S., Ciano K., Peck M., Wright A.L. Th1/Th2 patterns and balance in cytokine production in the parents and infants of a large birth cohort. J. Immunol. 2009, 182:3285-3293.
17. Harandi A.M. The potential of immunostimulatory CpG DNA for inducing immunity against genital herpes: opportunities and challenges. J. Clin. Virol. 2004, 30:207-210.
18. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
19. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., Jones R.W., Bullock R., Love S., Neal J.W., Zotova E., Nicoll J.A. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372:216-223.
20. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., St George-Hyslop P., Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408:979-982.
21. Kim H.D., Cao Y., Kong F.K., Van Kampen K.R., Lewis T.L., Ma Z., Tang D.C., Fukuchi K. Induction of a Th2 immune response by co-administration of recombinant adenovirus vectors encoding amyloid beta-protein and GM-CSF. Vaccine 2005, 23:2977-2986.
22. Kim H.D., Maxwell J.A., Kong F.K., Tang D.C., Fukuchi K. Induction of anti-inflammatory immune response by an adenovirus vector encoding 11 tandem repeats of Abeta1-6: toward safer and effective vaccines against Alzheimer's disease. Biochem. Biophys. Res. Commun. 2005, 336:84-92.
23. Kim H.D., Tahara K., Maxwell J.A., Lalonde R., Fukuiwa T., Fujihashi K., Van Kampen K.R., Kong F.K., Tang D.C., Fukuchi K. Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease. J Gene Med. 2007, 9:88-98.
24. Klinman D.M., Klaschik S., Tomaru K., Shirota H., Tross D., Ikeuchi H. Immunostimulatory CpG oligonucleotides: effect on gene expression and utility as vaccine adjuvants. Vaccine 2010, 28:1919-1923.
25. Lambracht-Washington D., Qu B.X., Fu M., Eagar T.N., Stüve O., Rosenberg R.N. DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model. JAMA 2009, 302:1796-1802.
26. Lambracht-Washington D., Qu B.X., Fu M., Anderson L.D., Stüve O., Eagar T.N., Rosenberg R.N. DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation. Cell. Mol. Neurobiol. 2011, 31:867-874.
27. Lemere C.A., Spooner E.T., LaFrancois J., Malester B., Mori C., Leverone J.F., Matsuoka Y., Taylor J.W., DeMattos R.B., Holtzman D.M., Clements J.D., Selkoe D.J., Duff K.E. Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol. Dis. 2003, 14:10-18.
28. Li H., Zou J., Yao Z., Yu J., Wang H., Xu J. Tetravalent Abeta1-15 vaccine reduces TCR-positive cell infiltration and up-regulates p75 in Tg2576 brains compared to Abeta42 vaccine. J. Neuroimmunol. 2010, 219:8-16.
29. Li Y., Ma Y., Zong L.X., Xing X.N., Sha S., Cao Y.P. Intranasal inoculation with an adenovirus vaccine encoding ten repeats of Aβ3-10 induces Th2 immune response against amyloid-β in wild-type mouse. Neurosci. Lett. 2011, 505:128-133.
30. Mandrekar S., Jiang Q., Lee C.Y., Koenigsknecht-Talboo J., Holtzman D.M., Landreth G.E. Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J. Neurosci. 2009, 29:4252-4262.
31. Matsumo Y., Sakuma H., Miyakoshi A., Tsukada Y., Kohyama K., Park I.K., Tanuma N. Characterization of relapsing autoimmune encephalomyelitis and its treatment with decoy chemokine receptor genes. J. Neuroimmunol. 2005, 170:49-61.
32. McLaurin J., Cecal R., Kierstead M.E., Tian X., Phinney A.L., Manea M., French J.E., Lambermon M.H., Darabie A.A., Brown M.E., Janus C., Chishti M.A., Horne P., Westaway D., Fraser P.E., Mount H.T., Przybylski M., St George-Hyslop P. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 2002, 8:1263-1269.
33. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
34. Mouri A., Noda Y., Hara H., Mizoguchi H., Tabira T., Nabeshima T. Oral vaccination with a viral vector containing Abeta cDNA attenuates age related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. FASEB J. 2007, 21:2135-2148.
35. Movsesyan N., Ghochikyan A., Mkrtichyan M., Petrushina I., Davtyan H., Olkhanud P.B., Head E., Biragyn A., Cribbs D.H., Agadjanyan M.G. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoS One 2008, 3:e2124.
36. Movsesyan N., Mkrtichyan M., Petrushina I., Ross T.M., Cribbs D.H., Agadjanyan M.G., Ghochikyan A. DNA epitope vaccine containing complement component C3d enhances anti-amyloid-beta antibody production and polarizes the immune response towards a Th2 phenotype. J. Neuroimmunol. 2008, 205:57-63.
37. Nagele R.G., D'Andrea M.R., Lee H., Venkataraman V., Wang H.Y. Astrocytes accumulate Abeta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res. 2003, 971:197-209.
38. Nagele R.G., Wegiel J., Venkataraman V., Imaki H., Wang K.C., Wegiel J. Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease. Neurobiol. Aging 2004, 25:663-674.
39. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 2003, 9:448-452.
40. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B.F., Boada M., Frank A., Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61:46-54.
41. Petrushina I., Ghochikyan A., Mktrichyan M., Mamikonyan G., Movsesyan N., Davtyan H., Patel A., Head E., Cribbs D.H., Agadjanyan M.G. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. J. Neurosci. 2007, 27:12721-12731.
42. Qu B., Rosenberg R.N., Li L., Boyer P.J., Johnston S.A. Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. Arch. Neurol. 2004, 61:1859-1864.
43. Qu B., Boyer P.J., Johnston S.A., Hynan L.S., Rosenberg R.N. Abeta42 gene vaccination reduces brain amyloid plaque burden in transgenic mice. J. Neurol. Sci. 2006, 244:151-158.
44. Qu B.X., Xiang Q., Li L., Johnston S.A., Hynan L.S., Rosenberg R.N. Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice. J. Neurol. Sci. 2007, 260:204-213.
45. Ruan L., Kang Z., Pei G., Le Y. Amyloid deposition and inflammation in APPswe/PS1dE9 mouse model of Alzheimer's disease. Curr. Alzheimer Res. 2009, 6:531-540.
46. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
47. Seabrook T.J., Thomas K., Jiang L., Bloom J., Spooner E., Maier M., Bitan G., Lemere C.A. Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice. Neurobiol. Aging 2007, 28:813-823.
48. Solomon B., Koppel R., Hanan E., Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:452-455.
49. Solomon B., Koppel R., Frankel D., Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:4109-4112.
50. Subramanian S., Divya Shree A.N. Enhanced Th2 immunity after DNA prime-protein boost immunization with amyloid beta (1-42) plus CpG oligodeoxynucleotides in aged rats. Neurosci. Lett. 2008, 436:219-222.
51. Torres K.C., Dutra W.O., Gollob K.J. Endogenous IL-4 and IFN-gamma are essential for expression of Th2, but not Th1 cytokine message during the early differentiation of human CD4+ T helper cells. Hum. Immunol. 2004, 65:1328-1335.
52. Vellas B., Black R., Thal L.J., Fox N.C., Daniels M., McLennan G., Tompkins C., Leibman C., Pomfret M., Grundman M., AN1792 (QS-21)-251 Study Team Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr. Alzheimer Res. 2009, 6:144-151.
53. Wang C.Y., Finstad C.L., Walfield A.M., Sia C., Sokoll K.K., Chang T.Y., Fang X.D., Hung C.H., Hutter-Paier B., Windisch M. Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease. Vaccine 2007, 25:3041-3052.
54. Wang C.Y., Wang T., Zheng W., Zhao B.L., Danscher G., Chen Y.H., Wang Z.Y. Zinc overload enhances APP cleavage and Aβ deposition in the Alzheimer mouse brain. PLoS One 2010, 5:e15349.
55. Wegiel J., Wang K.C., Tarnawski M., Lach B. Microglia cells are the driving force in fibrillar plaque formation, whereas astrocytes are a leading factor in plague degradation. Acta Neuropathol. 2000, 100:356-364.
56. Wegiel J., Wang K.C., Imaki H., Rubenstein R., Wronska A., Osuchowski M., Lipinski W.J., Walker L.C., LeVine H. The role of microglial cells and astrocytes in fibrillar plaque evolution in transgenic APP(SW) mice. Neurobiol. Aging 2001, 22:49-61.
57. Zou J., Yao Z., Zhang G., Wang H., Xu J., Yew D.T., Forster E.L. Vaccination of Alzheimer's model mice with adenovirus vector containing quadrivalent foldable Abeta(1-15) reduces Abeta burden and behavioral impairment without Abeta-specific T cell response. J. Neurol. Sci. 2008, 272:87-98.